odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
6164
10.69690/ODMJ-001-2612-6164
Original Research
Acute Promyelocytic Leukemia in Children: A report from the Pediatric Hematology and Oncology Department in Rabat
Naoual
El A.
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
naoual.elansari@gmail.com
Isfaoun
Z.
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
Lakhrissi
M.
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
Kili
A.
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
Khorassani
M. El
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
Hessissen
L.
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
Kababri
M. El
Pediatric Hematology and Oncology Department, Children’s Hospital, Rabat
26
12
2025
ODMJ-001-2612-6164
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
Acute Promyelocytic Leukemia
APL
pediatric hematology
Pediatric Hematology and Oncology
Rabat
production-ready-file-url
[
Testi AM, D’Angiò M, Locatelli F, et al. Acute promyelocytic leukemia (APL): comparison between children and adults. Mediterr J Hematol Infect Dis. 2014 Apr 15;6(1):e2014032.
]
[
Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015 Sep 20;33(27):2949-62.
]
[
Gurnari C, Voso MT, Girardi K, et al. Acute promyelocytic leukemia in children: a model of precision medicine and chemotherapy-free therapy. Int J Mol Sci. 2021 Jan 11;22(2):642.
]
[
Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21.
]
[
de Rooij JD, Zwaan CM, van den Heuvel-Eibrink M. Pediatric AML: from biology to clinical management. J Clin Med. 2015 Jan 9;4(1):127-49.
]
[
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.
]
[
Park KM, Yoo KH, Kim SK, et al. Clinical characteristics and treatment outcomes of childhood acute promyelocytic leukemia in Korea: a nationwide multicenter retrospective study by Korean Pediatric Oncology Study Group. Cancer Res Treat. 2022 Jan;54(1):269-76.
]
[
Andrade FG, Feliciano SVM, Sardou-Cezar I, et al. Pediatric acute promyelocytic leukemia: epidemiology, molecular features, and importance of GST-theta 1 in chemotherapy response and outcome. Front Oncol. 2021 Mar 19;11:642744.
]
[
Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005 Jul 15;106(2):447-53.
]
[
Ortega JJ, Madero L, Martín G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005 Oct 20;23(30):7632-40.
]
[
Imaizumi M, Tawa A, Hanada R, et al. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination with cytarabine in children with acute promyelocytic leukaemia: the Japanese Childhood Acute Myeloid Leukaemia Cooperative Study. Br J Haematol. 2011 Jan;152(1):89-98.
]
[
Grimwade D. The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol. 1999 Sep;106(3):591-613.
]
[
Sanz MA, Lo Coco F, Martín G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000 Aug 15;96(4):1247-53.
]
[
Lou Y, Ma Y, Sun J, et al. Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia. Ann Hematol. 2017 Nov;96(11):1793-800.
]
[
Testa U, Lo-Coco F. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Ann Hematol. 2016 Apr;95(5):673-80.
]
[
Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009 Feb 26;113(9):1875-91.
]
[
Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008 Feb 1;111(3):1078-84.
]
[
Montesinos P, Díaz-Mediavilla J, Debén G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009 Sep;94(9):1242-9.
]
[
Kutny MA, Alonzo TA, Abla O, et al. Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children’s Oncology Group AAML1331 trial. JAMA Oncol. 2022 Jan 1;8(1):79-87.
]
[
de Thé H, Le Bras M, Lallemand-Breitenbach V, et al. The cell biology of disease: acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol. 2012 Jul 9;198(1):11-21.
]
[
Huang DP, Yang LC, Chen YQ, et al. Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. Blood Cancer J. 2023 Dec 5;13(1):178.
]
[
Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7.
]